NCT00492921View on ClinicalTrials.gov

High-Dose Cyclophosphamide for Steroid Refractory GVHD

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Graft Versus Host Disease
Interventions
DRUG

Cyclophosphamide

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00492921 - High-Dose Cyclophosphamide for Steroid Refractory GVHD | Biotech Hunter | Biotech Hunter